NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
NanoViricides, Inc. (NYSE American: NNVC) announced its participation in the upcoming D. Boral Capital Global Conference, scheduled for May 7, 2026, at The Plaza Hotel in New York City. The company's president and executive chairman, Anil R. Diwan, Ph.D., will host one-on-one meetings with investors and interested parties from 9:45 a.m. to 2:45 p.m. ET. This event provides a platform for NanoViricides to discuss its clinical-stage pipeline and the progress of its lead drug candidate, NV-387.
The announcement comes at a critical time for NanoViricides as it advances NV-387, a broad-spectrum antiviral drug designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections. Notably, NV-387 has also shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles, underscoring its potential as a versatile therapeutic. The company has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events and is now focused on moving NV-387 into Phase II human clinical trials.
In addition to NV-387, NanoViricides is developing NV-HHV-1 for the treatment of all Herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (Shingles), and Chickenpox. However, the company cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to reliance on external collaborators and consultants.
The D. Boral Capital Global Conference offers NanoViricides an opportunity to engage with the investment community and highlight its unique approach to antiviral therapy. The company creates special purpose nanomaterials designed to target viruses directly, a strategy that could address significant unmet medical needs in infectious disease. The conference will be held at The Plaza Hotel, a prestigious venue that attracts a wide range of investors and industry professionals.
For more details on NanoViricides and its pipeline, the company's newsroom is available at https://ibn.fm/NNVC. The full press release regarding the conference participation can be accessed at https://ibn.fm/YxQyd.
This development is significant for NanoViricides as it seeks to advance its promising antiviral candidates through clinical trials. With NV-387's broad-spectrum activity and favorable safety profile, the company could play a key role in addressing current and future viral outbreaks. Investor attention will likely focus on updates regarding the initiation of Phase II trials and any additional data supporting the drug's efficacy.